The invention relates to an application of 2,2',2''-((2,4,6-trihydroxybenzene-1,3,5-triyl)tris(methanylylidene))tris(hydrazinecarbothioamide) in the preparation of antitumor drugs, especially in the preparation of anti-liver cancer drugs. Cell proliferation, cell morphology, cell colony formation, apoptosis, cell cycle, molecular biology and other experiments prove that the compound can effectively inhibit the proliferation of tumor cells, inhibit the tumor cell cloning formation, induce tumor cell apoptosis and affect the cycle of the tumor cells, has significant influences on proteins associated with tumor apoptosis, and has significant antitumor activity. The application provides a basis for the development of novel antitumor drugs, and the compound has a good clinical application prospect. The 2,2',2''-((2,4,6-trihydroxybenzene-1,3,5-triyl)tris(methanylylidene))tris(hydrazinecarbothioamide) which can be used as a pharmaceutically active ingredient and a pharmaceutically acceptablecarrier can be used to prepare an antitumor medicinal composition.